This oral drug is a potent and highly selective inhibitor that targets KIT D816V ... Over 90% of patients achieved at least 50% reduction in mast cell burden as measured by laboratory and bone ...

Mast cells, which are abundant in the airways of asthmatic individuals, act as first responders to viral infections by ...

Discover 8 ways mast cell activation syndrome causes widespread symptoms from digestive issues to brain fog, often mistaken for other conditions.

underscoring the importance of treating patients early in the ISM disease course -- -- BLU-808 healthy volunteer trial results demonstrate wide therapeutic window for modulating mast cell activity ...

At the recent AAAAI/WAO meeting, Blueprint Medicines Corp. presented the in vitro and in vivo characterization of BLU-808, a selective inhibitor of wild-type KIT, a transmembrane receptor tyrosine ...

For example, the LROs of mast cells contain lipid mediators ... or irreversible suppression of protease activity by a cognate inhibitor, which binds in the catalytic cleft of the protease and ...

Detailed price information for Celldex Therapeutics (CLDX-Q) from The Globe and Mail including charting and trades.

affirming potential as best- and first-in-class oral wild-type KIT inhibitor -- "We are incredibly proud to showcase our mast cell therapy portfolio at AAAAI / WAO, with 14 presentations ...